Table 3. Distribution of mutations between the different tumour subtypes.
| TC (%) | AC (%) | LCNEC (%) | SCLC (%) | |
|---|---|---|---|---|
| JAK3 (n=1) | 0 | 0 | 0 | 100 |
| NRAS (n=2) | 0 | 0 | 0 | 100 |
| RB1 (n=2) | 0 | 0 | 0 | 100 |
| VHL (n=1) | 0 | 0 | 0 | 100 |
| ATM (n=7) | 0 | 0 | 14 | 86 |
| TP53 (n=31) | 0 | 0 | 48 | 52 |
| ALK (n=2) | 0 | 0 | 50 | 50 |
| BRAF (n=3) | 0 | 0 | 67 | 33 |
| FGFR2 (n=1) | 0 | 0 | 100 | 0 |
| PIK3CA (n=8) | 0 | 13 | 13 | 75 |
| ERBB4 (n=5) | 0 | 20 | 40 | 40 |
| KDR (n=3) | 0 | 33 | 67 | 0 |
| KRAS (n=3) | 0 | 33 | 67 | 0 |
| MET (n=3) | 0 | 33 | 67 | 0 |
| SMARCB1 (n=2) | 0 | 50 | 0 | 50 |
| FGFR1 (n=2) | 0 | 50 | 50 | 0 |
| KIT (n=2) | 0 | 100 | 0 | 0 |
| PTEN (n=1) | 0 | 100 | 0 | 0 |
| SMO (n=1) | 0 | 100 | 0 | 0 |
| HNF1A (n=1) | 0 | 100 | 0 | 0 |
| RET (n=7) | 14 | 14 | 14 | 58 |
| EGFR (n=7) | 14 | 29 | 14 | 43 |
| APC (n=7) | 14 | 29 | 14 | 43 |
| ERBB2 (n=11) | 18 | 18 | 27 | 36 |
| ABL1 (n=5) | 20 | 0 | 40 | 40 |
| PDGFRA (n=4) | 25 | 0 | 25 | 50 |
| IDH (n=5) | 40 | 0 | 0 | 60 |
| GNAS (n=2) | 50 | 50 | 0 | 0 |
| SMAD4 (n=1) | 100 | 0 | 0 | 0 |
Abbreviations: AC=atypical carcinoid; LCNEC=large-cell neuroendocrine carcinoma; SCLC=small-cell lung cancer; TC=typical carcinoid.
JAK3, NRAS, RB1 as well as VHL variants were exclusively found in SCLCs, whereas the FGFR2 mutation was only detected in LCNEC. The KIT, PTEN and SMO alterations were determined in ACs and the SMAD4 variant in TC subtype only.